Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENA-001 Single Ascending Dose Study
NCT06967259Phase 1Completed
- Sponsor
- Enalare Therapeutics
- Start
- May 2025
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in respiratory depression comparing ENA-001 Treatment Arm with Placebo Treatment Arm (2 arms). Primary endpoints: Range values of laboratory tests at 8 weeks, Range values of special chemistry tests at 8 weeks and 4 more. Started May 2025; status: completed.
02
Drugs
ENA-001
03
Conditions
respiratory depression
Beyond the preview
Go deeper on NCT06967259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06967259.